Navigation Links
Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data from fifteen presentations by the company and its collaborators at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating preclinical advances with its proprietary antibody-drug conjugate (ADC) technology and cancer product pipeline.

ADCs are monoclonal antibodies linked to cell-killing drugs. Seattle Genetics' ADC technology employs synthetic, highly potent drugs that are bound to monoclonal antibodies through proprietary linker systems. The linkers are designed to be stable in the bloodstream but to release the drug payload under specific conditions once inside target cells, thereby sparing non-target cells many of the toxic effects of traditional chemotherapy.

"Empowered antibodies utilizing our ADC technology have the potential to significantly impact the way cancer is treated," said Clay B. Siegall, Ph.D., President and Chief Executive Officer at Seattle Genetics. "Our strong presence at AACR this year reflects continued progress with our proprietary and partnered ADC programs. We expect to report clinical data from the ongoing phase I dose-escalation trial of SGN-35, our lead ADC, later this year, while both we and our collaborators continue to advance additional ADC programs into and towards the clinic."

ADC Programs

Researchers reported preclinical data at AACR describing how changes in the structure of the attached drugs can affect ADC efficacy and tolerability, the impact that linker structure and these modifications can have on ADC activity, and the ability of Seattle Genetics' ADC technology to effectively deliver active drugs to target tissue while avoiding non-targeted drug release. (Abstracts #4793, #916 and #4088) Further data from preclinical models of ADCs provide mechanistic insight into how and when drugs are r eleased inside of target cells. (Abstracts #658 and #4086)

In addition, data were reported on preclinical studies of ADCs targeted to glypican-3, CD133/prominin-1 and Lewis-Y, which are expressed in a variety of carcinomas including melanoma, ovarian, brain, colorectal and pancreatic cancers. Data were presented in multiple poster sessions demonstrating that ADCs to these targets are active and thus have therapeutic potential in the treatment of multiple types of solid tumors. (Abstracts #656, #1332 and #3332)

Several of Seattle Genetics' collaborators presented additional preclinical data on programs utilizing the company's ADC technology. These included presentations by Progenics, Genentech, MedImmune and Celera, an Applera Corporation business. (Abstracts #4102, #1551, #4468, #5744 and #1324)

SGN-33 and SGN-30 Programs

Data presented during AACR also illustrate ongoing preclinical activities with SGN-33 and SGN-30 to further define their therapeutic potential.

SGN-33 is a humanized monoclonal antibody currently in a single-agent phase I clinical trial for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In preclinical studies, SGN-33 reduces the tumor-induced activity of macrophages, suggesting a novel mechanism that may contribute to its antitumor activity. Seattle Genetics plans to advance SGN-33 into combination clinical trials during 2007, including a phase I study in combination with Revlimid(R) for MDS and a phase II study in combination with low-dose chemotherapy for AML. (Abstract #4111)

SGN-30 is currently in three phase II clinical trials in combination with chemotherapy for the treatment of Hodgkin's disease and anaplastic large cell lymphoma (ALCL) that are sponsored by the National Cancer Institute. Preclinical findings presented by the company during AACR further characterize SGN-30's mechanism of action. (Abstract #661)

Downloadable copies of Seattle Genetics' posters are available f rom the "Technology" section of the company's website at

About Seattle Genetics

Seattle Genetics is a biotechnology company developing monoclonal antibody-based therapies for the treatment of multiple types of cancer, including lymphoma, multiple myeloma, leukemia and solid tumors. The company has an exclusive worldwide license agreement with Genentech to develop and commercialize SGN-40. Seattle Genetics also has three other proprietary programs in ongoing clinical trials: SGN-33, SGN-35 and SGN-30. In addition, the company has developed proprietary antibody-drug conjugate (ADC) technology comprised of highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics and MedImmune, as well as an ADC co-development agreement with Agensys. More information can be found at

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the potential therapeutic potential of Seattle Genetics' product candidates and ADC technology. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks related to adverse clinical results as our product candidates move into and advance in clinical trials, risks inherent in early stage development and failure by Seattle Genetics' collaborators to advance product candidates incorporating its technology. More information about the risks and uncertainties faced by Seattle Genetics is contained in Seattle Genetics' filings with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Seattle Genetics, Inc.
Peggy Pinkston, Corporate Communications, 425-527-4160


Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
3. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
4. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
5. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
6. Myriad Genetics Presents Tumor Origin Technology at AACR
7. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
8. Myriad Genetics Presents Azixas Mode of Action at AACR
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & ... (TGIG), has initiated cultivation and processing operations at its production facility, and opened ... , Puradigm is the manufacturer of a complete system of proactive air and ...
Breaking Medicine News(10 mins):